Use of PD-1 inhibitors in patients with end-stage renal disease: safety and clinical outcomes from real-world data

References

• Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016;27(4):559–574.
   PubMed Web of Science ®Google Scholar
• Keytruda (pembrolizumab) [package insert]. Kenilworth, NJ: Merck & Co., Inc; 2/2022.
   Google Scholar
• Opdivo (nivolumab) [package insert]. New York, NY: Bristol Myers Squibb; 3/2022.
   Google Scholar
• Na SY, Sung JY, Chang JH, et al. Chronic kidney disease in cancer patients: an independent predictor of cancer-specific mortality. Am J Nephrol. 2011;33(2):121–130.
   PubMed Web of Science ®Google Scholar
• Maisonneuve P, Agodoa L, Gellert R, et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999;354(9173):93–99.
   PubMed Web of Science ®Google Scholar
• Tang SQ, Tang LL, Mao YP, et al. The pattern of time to onset and resolution of Immune-Related adverse events caused by immune checkpoint inhibitors in cancer: a pooled analysis of 23 clinical trials and 8,436 patients. Cancer Res Treat. 2021;53(2):339–354.
   PubMed Web of Science ®Google Scholar
• Cathcart-Rake EJ, Sangaralingham LR, Henk HJ, et al. A population-based study of immunotherapy-related toxicities in lung cancer. Clin Lung Cancer. 2020;21(5):421–427 e2.
   PubMed Web of Science ®Google Scholar
• Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84(5):548–558.
   PubMed Web of Science ®Google Scholar
• Le Louedec F, Leenhardt F, Marin C, et al. Cancer immunotherapy dosing: a pharmacokinetic/pharmacodynamic perspective. Vaccines (Basel). 2020;8(4):632.
   Web of Science ®Google Scholar
• Betjes MG. Immune cell dysfunction and inflammation in end-stage renal disease. Nat Rev Nephrol. 2013;9(5):255–265.
   PubMed Web of Science ®Google Scholar
• Hartzell S, Bin S, Cantarelli C, et al. Kidney failure associates with T cell exhaustion and imbalanced follicular helper T cells. Front Immunol. 2020;11:583702.
   PubMed Web of Science ®Google Scholar
• Centanni M, Moes D, Troconiz IF, et al. Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors. Clin Pharmacokinet. 2019;58(7):835–857.
   PubMed Web of Science ®Google Scholar
• Kuo MC, Su PJ, Huang CC, et al. Safety and efficacy of immune checkpoint inhibitors for patients with metastatic urothelial carcinoma and End-Stage renal disease: Experiences from Real-World practice. Front Oncol. 2020;10:584834.
   PubMed Web of Science ®Google Scholar
• Jain J, Stein J, Garje R. Evaluation of checkpoint inhibitors in cancer patients with end-stage renal disease on hemodialysis: Case series and review of the literature. J Immunother. 2020;43(8):244–249.
   PubMed Web of Science ®Google Scholar
• Vitale MG, Baldessari C, Milella M, et al. Immunotherapy in Dialysis-Dependent cancer patients: Our experience in patients with metastatic renal cell carcinoma and a review of the literature. Clin Genitourin Cancer. 2019;17(5):e903–e908.
   PubMed Web of Science ®Google Scholar
• Tachibana H, Kondo T, Ishihara H, et al. Safety and efficacy of nivolumab in patients with metastatic renal cell carcinoma and end-stage renal disease at 2 centers. Clin Genitourin Cancer. 2019;17(4):e772–e778.
   PubMed Web of Science ®Google Scholar
• Cheun H, Kim M, Lee H, et al. Safety and efficacy of immune checkpoint inhibitors for end-stage renal disease patients undergoing dialysis: a retrospective case series and literature review. Invest New Drugs. 2019;37(3):579–583.
   PubMed Web of Science ®Google Scholar
• Wang PF, Chen Y, Song SY, et al. Immune-related adverse events associated with anti-PD-1/PD-L1 treatment for malignancies: a meta-analysis. Front Pharmacol. 2017;8:730.
   PubMed Web of Science ®Google Scholar
• Apalla Z, Papageorgiou C, Lallas A, et al. Cutaneous adverse events of immune checkpoint inhibitors: a literature review. Dermatol Pract Concept. 2021;11(1):e2021155.
   PubMedGoogle Scholar
• Hsiehchen D, Watters MK, Lu R, et al. Variation in the assessment of immune-related adverse event occurrence, grade, and timing in patients receiving immune checkpoint inhibitors. JAMA Netw Open. 2019;2(9):e1911519.
   PubMed Web of Science ®Google Scholar
• Kotwal A, Kottschade L, Ryder M. PD-L1 Inhibitor-Induced thyroiditis is associated with better overall survival in cancer patients. Thyroid. 2020;30(2):177–184.
   PubMed Web of Science ®Google Scholar
• Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020;70(2):86–104.
   PubMed Web of Science ®Google Scholar
• Kitchlu A, Jhaveri KD, Sprangers B, et al. Immune checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review. Clin Kidney J. 2021;14(9):2012–2022.
   PubMed Web of Science ®Google Scholar
• Naylor KL, Kim SJ, McArthur E, et al. Mortality in incident maintenance dialysis patients versus incident solid organ cancer patients: a Population-Based cohort. Am J Kidney Dis. 2019;73(6):765–776.
   PubMed Web of Science ®Google Scholar